Kornimate/medical-research-clean huggingface dataset:
physical therapy treatments, including neural mobilization and hip/back stretches for people between 50-89 with lumbar spinal stenosis and leg pain provoked by walking

Conditions: Lumbar Spinal Stenosis

Summary: aging of the back is common in the older people and can result in difficulties standing and walking. conservative treatment is recommended before considering surgery. some recommended exercises involve the use of expensive equipment. the present study plans to evaluate if specifically moving the nerves in the legs/back and improving flexibility of the hip and back can benefit patients. these exercises require no equipment, are simple to perform, and can provide patients a way to continue to perform these exercises at home. the purposes of this study are to (1) observe the benefit of a treatment program involving moving the nerves of the leg/back, stretching the legs and low back in patients with low back pain and difficulties walking; and (2) determine if benefits received remain at a 3-month follow-up.


Eligibility criteria:
inclusion criteria: * adults aged between 50-89 years old * intermittent unilateral or bilateral leg pain occurring with walking and standing activities that is relieved only with sitting or by assuming flexed positions * magnetic resonance imaging (mri) confirmation of lumbar spinal stenosis * leg symptoms greater than 4/10 and provoked within 15 minutes of walking exclusion criteria: * prior lumbar surgery * spinal injection in last 6 weeks * impaired walking tolerance due to factors other than neurogenic claudication * inability to follow the rater's instructions * any medical contra-indication for hip mobilizations in extension or flexion * current medico-legal issues

Keywords: degenerative lumbar spinal stenosis neural mobilization hip extension mobilization case series neurogenic claudication
knee prosthetic joint infection antibiotic elution

Conditions: Prosthetic-joint Infection; Arthroplasty Complications

Summary: patients presenting with prosthetic joint infections of a total knee replacement who are treated with an antibiotic spacer will be observed prospectively for their response to treatment and antibiotic elution profiles will be measured post-operatively utilizing mass spectrometry from synovial fluid acquired as part of standard of care in the management of prosthetic joint infection. secondary outcomes including post-operative complications, re-operation rates, and re-admission rates will also be compared.

the current study aims to assess the surgical and patient-reported outcomes and in vivo antibiotic elution profile of the management of total knee arthroplasty (tka) prosthetic joint infection (pji). within the standard of care, tka pji is treated via a resection arthroplasty and antibiotic cement spacer placement. patients will be enrolled if they are undergoing surgical management for a chronic tka pji and will receive surgical treatment according to the standard of care. in the post-operative period, patients will be monitored for surgical and patient-reported outcomes including re-operation rate, pain scores, complication rates, and re-infection rates. synovial fluid obtained from intra-articular postoperative drains and at postoperative knee aspirations during reimplantation evaluations will also be utilized for antibiotic concentration quantification via mass spectrometry, if sufficient specimen is available. patient who undergo surgical management for their chronic tka pji will then have their measured antibiotic elution concentrations compared. the study hypothesizes that patients undergoing treatment of a pji with antibiotic spacer + antibiotic cement spacer will have better surgical and patient-related outcomes with higher antibiotic elution concentrations. these improved outcomes would include lower re-operation rates, lower pain scores, lower wound healing complications, and higher rates of second stage re-implantation observed in patients with higher antibiotic elution concentrations. specific aims: 1. to evaluate the antibiotic elution profile and post-operative intra-synovial concentrations in the treatment of chronic pji after tka. 2. to evaluate surgical and patient-related outcomes in chronic tka pji patients following implant resection and knee spacer placement, including amount of post-operative drain output, wound healing complications, 30- and 90-day risk of re-operation, pain scores, and rate of second stage re-implantation.

Eligibility criteria:
inclusion criteria: * patients planned for treatment of a total knee arthroplasty prosthetic joint infection * patients greater than 18 years of age * patients able to provide informed consent exclusion criteria: * prior history of ipsilateral or contralateral prosthetic joint infection warranting operative management * patients less than 18 years of age * patients unable to provide informed consent.

Keywords: prosthetic joint infection revision total knee arthroplasty antibiotic elution profile
investigation of genetic risk of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the atrial fibrillation (af) is the most common cardiac rhythm disturbance that is responsible for substantial morbidity and mortality independent of associated heart disease or other risk factors. even in the absence of preexisting cardiovascular disease, af remains significantly associated with excess mortality rates. the current unsatisfactory treatment for af comes from lack of understanding of the pathophysiology of af. the purpose of this study is to identify gene polymorphisms that confer susceptibility to atrial fibrillation. patients with af（n=500） and healthy volunteer（n=1000） without af are enrolled in this study. patients with coronary artery disease, severe valvular heart disease, cardiomyopathy or heart failure were excluded from the study.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of atrial fibirillation exclusion criteria: * coronary artery disease * severe valvular heart disease * cardiomyopathy * heart failure

Keywords: atrial fibrillation
laser in-situ keratomileusis with crosslinking compared to conventional lasik in patients with high myopia

Conditions: Myopia; Myopic Astigmatism; Crosslinking; Corneal Ectasia; Myopic Regression

Summary: the objectives of this study are to evaluate the safety and efficacy of a treatment regimen for high myopia and myopic astigmatism: lasik followed by crosslinking performed with the kxl crosslinking-system and vibex xtra (riboflavin ophthalmic solution, avedro, usa), as compared to lasik alone, with regards to regression of refractive outcome, as measured by manifest refraction spherical equivalent (mrse) and keratometry.

this is a controlled study of the safety and efficacy of the kxl system and vibex xtra (riboflavin ophthalmic solution, avedro, usa) for performing crosslinking in eyes undergoing lasik for high myopia or myopic astigmatism. each subject will have bilateral lasik performed and one eye will be randomized to undergo lasik followed by crosslinking. subjects will undergo bilateral lasik. following randomisation one eye of each subject will be treated with vibex xtra (riboflavin ophthalmic solution) following lasik and will be irradiated with the kxl system at 30 mw/cm2 intensity for 90 seconds continuous uv-a light treatment for a total radiant exposure of 2.7 j /cm2. all eyes will be assessed at 1 day, 1, 3, 6, and 12 months after treatment.

Eligibility criteria:
inclusion criteria: * eligible for bilateral myopic fs-lasik with -6.00 to -12.00 d (diopters) with a maximum of 5.00 d astigmatism * age \> 18 years * provided written informed consent * difference between the mrse and cycloplegic se less than 0.75 d * mrse needed to be stable for the last 12 months (\<0.5 d). exclusion criteria: * prior corneal surgery, * forme fruste or manifest keratoconus, * history of corneal scarring, melting, ulceration * repeating inflammations of the eye * taking vitamin c 1 week prior to the treatment
capecitabine as neoadjuvant therapy in locally advanced breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to assess the safety and effectiveness of capecitabine before surgery. the study will also help gain more information about the effects of the capecitabine on physical and emotional well-being and how well the participants on capecitabine follow the study drug plan.


Eligibility criteria:
inclusion criteria: * patients with locally advanced, histologically confirmed adenocarcinoma of the female breast. women with ulcerated breast lesions may be enrolled. patients with asymptomatic metastases to the bone are eligible. * ability to provide written informed consent prior to study-specific screening procedures * tnm stage:t3-4, n0-3 m0; patients with asymptomatic bone metastases may be enrolled. patients with large t2 tumors whose surgeons believe their results with breast conserving surgery will be improved by neoadjuvant therapy may be enrolled. * age 18 years or older * negative serum or urine pregnancy test within 7 days prior to starting therapy (female patients of childbearing potential). * performance status 0-1 * required initial laboratory data: * granulocytes \>=1,200/µl * platelet count \>=100,000/µl * calculated creatinine clearance \> 30 ml/min * total bilirubin \<= upper limit normal * alkaline phosphatase \<=upper limit normal * sgpt, sgot \<=upper limit normal * normal chest x-ray exclusion criteria: * her2 positive breast cancer * pregnant or lactating woman * life expectancy \< 3 months * serious, uncontrolled, concurrent infection(s) * any prior fluoropyrimidine therapy or other chemotherapy * prior unanticipated severe reaction to fluoropyrimidine therapy, or known hyper-sensitivity to 5-fluorouracil or known dpd deficiency. * patients who have received more than four weeks of tamoxifen therapy for this malignancy. * treatment for other carcinomas within the last five years, except cured non- melanoma skin and treated in-situ cervical cancer. * participation in any investigational drug study within 4 weeks preceding the start of study treatment. * evidence of metastatic disease to sites other than the bone or with symptomatic bone lesions. * other serious uncontrolled medical conditions that the investigator feels might compromise study participation. * lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome. * known, existing uncontrolled coagulopathy or concurrent treatment with coumadin and phenytoin * any of the following laboratory values: * abnormal hematologic values (neutrophils \< 1.0 x 109/l, platelet count \< 100 x 109/l) * impaired renal function (estimated creatinine clearance \<30ml/min as calculated with cockcroft-gault equation) * serum bilirubin \> upper normal limit. * sgot, sgpt \> upper normal limit

Keywords: breast cancer neoadjuvant locally advanced
evaluation of ultraaccelerated high dose rate intrauterine interventional radiotherapy

Conditions: Locally Advanced Cervical Carcinoma

Summary: to evaluate the degree of acute and long-term intestinal, urinary and vaginal toxicity, and the impact on sexual activity of an accelerated fractionation of high dose rate interventional radiotherapy (irt-hdr) in patients with locally advanced cervical cancer (ib2 - va, n+/-).

observational, monocentric and prospective study. all patients with locally advanced cervix cancer will be underwent to radiochemotherapy followed by accelerated interventional radiotherapy (brachytherapy). fist endpoints wer severe acute and late gastrointestinal, and urinary toxicities and sexual activity.

Eligibility criteria:
inclusion criteria: * age ≥18 years * ecog 0-2 * histological diagnosis of squamous carcinoma and/or adenocarcinoma of the uterine cervix * figo ib2 stadium - iva (staging 20018) * no contraindications to performing mri of the pelvis * informed consent exclusion criteria: * age \<18 years * ps \>2 * previous cancer in the last 10 years * previous radiation treatment in the region of interest * presence of pathologies that contraindicate radiotherapy treatment (genetic syndromes of hyper-radiosensitivity, ulcerative colitis, diverticulitis in the acute phase, severe diverticulosis, chronic pelvic inflammation) * presence of internal diseases that contraindicate chemotherapy or radio-chemotherapy treatment (severe liver disease, heart disease, renal failure, etc.) * presence of distant metastases in sites other than the pelvic lymph nodes * any significant medical condition that in the opinion of the investigator may interfere with the patient's optimal participation in the study

Keywords: cervical carcinoma interventional radiotherapy acute and late toxicities radiochemotherapy
application of telemedicine to the management of aggressive lymphomas

Conditions: Lymphoma

Summary: the purpose of this study is to evaluate the value of ama in a comparative multicenter regional study as a reference for aggressive lymphoma. the primary endpoint will be rdi. this study consider that the ama support should allow a significant improvement of the rdi compared to the control group and thus impact the duration without progression. the study covers 350 patients recruited from 10 regional centers.


Eligibility criteria:
inclusion criteria: * patient with a recent diffuse large b cell lymphoma (lbdgc), histologically proven, with treatment not started * a priori likely to be treated by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (r-chop21) for 8 cycles or rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (r-acvbp). * index international prognosis (ipi) measurable (ipi-aa), adjusted for age. any ipi-aa is eligible. * accepting the study exclusion criteria: * patient with another type of lymphoma (including transformed follicular forms) * patient having already started his treatment. * life expectancy \<3 months. * carcinologic history * serum positive for hiv or hepatitis b virus (hbv).
training on using ıinsulin in patients with type 2 diabetes

Conditions: Insulin Dependent Diabetes; Diabetes type2

Summary: this study was conducted to evaluate the effect of individual insulin use training given to patients with type 2 diabetes using insulin on safe drug administration, pain level and perception of treatment. the study was conducted between october 2022 and march 2023 with a randomized control group.

objective: the aim of this study was to examine the effects of individual insulin use training given to patients with type 2 diabetes on safe drug administration, pain level and treatment perception, and to contribute to both national and international literature. method: it was conducted between october 2022 and march 2023 as a randomized controlled study in a pre-test-post-test order to determine the effect of individual insulin use education given to patients with type 2 diabetes on safe drug administration, pain level and treatment perception. the data were collected by the researchers with the descriptive information form of the patients, the insulin administration skill observation form, the visual analogue scale and the insulin therapy evaluation scale. data collection: face-to-face and individual interviews with patients who applied to the internal diseases and endocrinology polyclinic and diabetes nursing polyclinics of a state hospital in a city located in the southeastern anatolia region of turkey, and who were hospitalized in the internal diseases, endocrinology, physical therapy and rehabilitation and cardiology services. collected using the method. a pilot study was not conducted before starting the study. before the study, all patients were informed about the study and their verbal and written consents were obtained.

Eligibility criteria:
inclusion criteria: patients included in the study; * 18 years and over using insulin injections for at least six months or longer * meeting the american diabetes association (ada, 2021) diagnostic criteria for type 2 diabetes * no communication and mental problems * insulin injection made by himself or his family the patients who agreed to participate in the study. exclusion criteria: patients excluded from the study; * self or family member health personnel those with advanced retinopathy, nephropathy, neuropathy * diagnosed with type 1 diabetes * pregnant or breastfeeding women * patients who participated in another clinical trial concurrently or within 1 month prior to the start of the trial.

Keywords: tip 2 diyabet güvenli i̇laç kullanımı tedavi algısı i̇nsülin
a multiple ascending dose study to evaluate safety and tolerability of bfkb8488a in participants with type 2 diabetes mellitus and participants with non-alcoholic fatty liver disease

Conditions: Diabetes Mellitus, Type 2; Non-Alcoholic Fatty Liver Disease

Summary: this is a phase ib, randomized, blinded, placebo-controlled, multiple ascending-dose study of the safety, tolerability, pharmacokinetic (pk), and pharmacodynamic (pd) effects of bfkb8488a in participants with type 2 diabetes mellitus (t2dm) and participants with non-alcoholic fatty liver disease(nafld). a maximum of approximately 160 participants will be enrolled across multiple sites in the united states. participants will be randomly assigned to receive study drug (active bfkb8488a or placebo). the study will consist of a screening period (up to 8 weeks), a 12-week treatment period, and a 6-week follow-up period. participants may come to clinic for an optional pre-screening visit.


Eligibility criteria:
inclusion criteria: for t2dm cohort only: * body mass index (bmi) ≥ 27 kg/m2 and ≤ 40 kg/m2. * a confirmed diagnosis of type 2 diabetes ≥ 6 months at screening * current stable treatment (at least 3 months) for diabetes * hemoglobin a1c (hba1c) ≥ 6.8% and ≤ 9.0%. * for women of childbearing potential, agreement to remain abstinent or use reliable contraception during treatment period and for at least 42 days after last dose of study drug * for men, agreement to remain abstinent or use reliable contraception and agree to refrain from donating sperm * for nafld cohort only: * bmi ≥ 25 kg/m2 and ≤ 40 kg/m2 * at screening, confirmed liver fat by ultrasound or calculated liver fat ≥ 10% using variables from the nafld liver fat score * hepatic steatosis on magnetic resonance imaging (mri; ≥ 10% average liver proton density fat fraction \[pdff\]) prior to randomization. exclusion criteria: * pregnant, lactating, or intending to become pregnant within 42 days after the last dose of study drug is administered * suspected or confirmed diagnosis of type 1 diabetes * significant cardiac disease * any psychiatric illness that increases the risk of participation in the study * history of severe allergic, anaphylactic, or other hypersensitivity reactions, or severe systemic bacterial, fungal, or parasitic infections * poor peripheral venous access * received blood products within 2 months before dosing * donation or loss of blood within 30-56 days prior to study drug administration * positive for hepatitis c virus (hcv) antibody, hepatitis b surface antigen (hbsag), or human immunodeficiency virus (hiv) antibody * liver enzymes greater than acceptable limits * history of eating disorders or surgical procedures for weight loss * active participation in a structured weight loss or dietary program * treatment with investigational therapy or exposure to any biological therapy * illicit drug use, marijuana use, or alcohol abuse * current use of more than one pack of cigarettes a day or equivalent nicotine- containing products * any serious medical condition or abnormality in clinical laboratory tests
inverted ilm-flap techniques variants for macular hole surgery: outcomes comparison

Conditions: Macular Holes

Summary: to report closure rate, best corrected visual acuity (bcva), retinal sensitivity (rs) and fixation stability (fs) of idiopathic macular holes (mh) randomized to cover group (cg) or fill group (fg) of the inverted internal limiting membrane (ilm) flap surgical procedure.

patients will be randomized (1:1) to receive a vitrectomy with either cover or fill ilm flap technique. "cover" when the ilm flap is everted over the mh gap in a single layer, "fill" when the ilm is folded into multiple layers within the mh. all patients will undergo bcva, rs and fs assessment at baseline, 1-month and 3-months after surgery. purpose of the study is to report retinal differential sensitivity and fixation stability as well as anatomic and visual outcomes of patients operated on for idiopathic mh and randomly assigned to fill or cover groups.

Eligibility criteria:
inclusion criteria: * patients with idiopatic macular holes exclusion criteria: * patients with mh duration greater than 6 months * myopia exceeding 6 diopters * history of trauma * previous ocular surgery except uncomplicated cataract extraction with in-the-bag iol implantation * any ocular illness including glaucoma, uveitis, optic nerve pathology
elmex gel efficacy in preventing white spot lesions

Conditions: Dental Caries

Summary: the objective of this phase iv study: to establish the efficacy of elmex gel with a fluoride concentration of 1.25% compared with placebo by determining prevention of white spot lesions in patients wearing fixed orthodontic appliances.

314 healthy subjects undergoing orthodontic treatment will be examined. follow up will take place from bonding the appliance till debonding, at least 12 months and no more than 30 months. tooth brushing with product (test product or control) once per week during the entire study. 4 times a year additional tray application of test product or control. subjects wiil clean their teeth with the toothpaste they usually use during the entire study. toothbrush and a sandglass will be provided every 6 weeks

Eligibility criteria:
inclusion criteria: * treatment plan: minimum of 10 teeth to be bonded labially at least 10 years old * written declaration of informed consent exclusion criteria: * known allergy to components of test products * handicapped patients who have difficulties brushing their teeth * pathological desquamation changes * known pregnancy, breast feeding * eating disorders * disease that effect dental hard tissue * participation in another clinical trial either currently or within the lase 30 days

Keywords: amine fluoride white spot lesions qlf